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Background: In cancer radiotherapy, knowledge of normal tissue responses and toxicity risks is essential in order to
deliver the highest possible absorbed dose to the tumor while maintaining normal tissue exposure at non-critical
levels. However, few studies have investigated normal tissue responses in vivo after 211At administration. In order to
identify molecular biomarkers of ionizing radiation exposure, we investigated genome-wide transcriptional responses
to (very) low mean absorbed doses from 211At in normal mouse tissues.
Methods: Female BALB/c nude mice were intravenously injected with 1.7 kBq 211At and killed after 1 h, 6 h, or 7 days
or injected with 105 or 7.5 kBq and killed after 1 and 6 h, respectively. Controls were mock-treated. Total RNA
was extracted from tissue samples of kidney cortex and medulla, liver, lungs, and spleen and subjected to microarray
analysis. Enriched biological processes were categorized after cellular function based on Gene Ontology terms.
Results: Responses were tissue-specific with regard to the number of significantly regulated transcripts and associated
cellular function. Dose rate effects on transcript regulation were observed with both direct and inverse trends. In several
tissues, Angptl4, Per1 and Per2, and Tsc22d3 showed consistent transcript regulation at all exposure conditions.
Conclusions: This study demonstrated tissue-specific transcriptional responses and distinct dose rate effects after 211At
administration. Transcript regulation of individual genes, as well as cellular responses inferred from enriched transcript
data, may serve as biomarkers in vivo. These findings expand the knowledge base on normal tissue responses and may
help to evaluate and limit side effects of radionuclide therapy.
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In nuclear medicine, treatment using radiolabeled tumor-
seeking agents is a vital option for patients with, e.g., metas-
tases or inoperable tumors [1]. 211At is a synthetic α-emitter
with metalloid and halogen characteristics and a mean linear
energy transfer (LET) value that is nearly optimal for
inducing double-strand breaks (DSB) in DNA [2,3].
As such, 211At has a high biological effectiveness for
cell killing which renders it a promising candidate for* Correspondence: britta.langen@gu.se
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in any medium, provided the original work is pradiolabeling in radionuclide therapy [3-7]. However, 211At
can be liberated from a carrier molecule in vivo during
degradation or metabolism and be retained in normal tis-
sues [8-10]. Unbound 211At is accumulated in the thyroid
gland through a mechanism similar to iodide resulting
in high uptake and absorbed dose [9-15]. In other tis-
sues, 211At uptake occurs at lower levels, although gener-
ally higher than for iodide, with tissue-specific differences
leading to differential exposure to ionizing radiation
throughout the body [8-10]. The increased uptake of 211At
in non-thyroid tissues compared to, e.g., iodide increases
the radiation risk and side effects in healthy tissues after
treatment with 211At-labeled tumor-targeting agents. A
detailed understanding of normal tissue responses is
needed to establish accurate tolerance doses and thusan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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nuclear medicine routinely uses nude mice to study tumor
xenografts and, for instance, anti-tumor effects of targeted
therapy. However, little is known about the quality and
quantity of normal tissue effects in vivo, which is an
important aspect for robust analysis and establishment
of both effective and safe treatment parameters.
Many studies for biomarker discovery of ionizing radi-
ation effects have been performed with in vitro model
systems and external irradiation, predominantly γ-rays
and X-rays [16,17]. In contrast, knowledge on basic tis-
sue responses in vivo to internal radionuclide exposure is
still scarce, specifically with regard to α-emitters and low
absorbed dose. Within the framework of the European
project Low Dose Research towards Multidisciplinary In-
tegration (DoReMi), Pernot and colleagues summarized
that ‘changes in RNA levels identified by transcriptomics’
had ‘unknown sensitivity’ and that ‘specificity to ionizing
radiation and confounders (was) unknown at present time’
[18]. In previous studies on mice, we used intravenously
administered 211At in the 0.064- to 42-kBq range and
characterized genome-wide transcriptional responses after
24 h in various normal tissues: in thyroid [19] and in
kidney cortex and medulla, liver, lungs, and spleen
[20]. Radiation-induced cellular responses were dem-
onstrated as complex and tissue-specific and to vary
with absorbed dose level in a non-linear manner, which
advises caution for extrapolation or interpolation of re-
sponses between absorbed dose levels [19,20]. Further-
more, comparatively few previously proposed ionizing
radiation-associated genes from in vitro studies were dif-
ferentially regulated, which demonstrated the need to iden-
tify biomarker genes in an in vivo setting. Despite
pronounced differences in absorbed dose levels between
thyroid and non-thyroid tissues, the total significant tran-
script regulation showed similar characteristics between
all tissues, i.e., a distinct shift in regulation intensity
between 0.64 and 1.8 kBq 211At. These findings sug-
gested that responses in non-thyroid tissues were not
only due to low-dose effects from 211At but also sub-
ject to systemic effects from, e.g., the 211At-accumulat-
ing thyroid gland [20]. These studies highlight the
necessity to further expand the knowledge base on
low-dose responses to ionizing radiation in vivo while
regarding induced effects in a systemic and physio-
logical context.
In this exploratory study, transcriptional gene expres-
sion responses were analyzed on a genome-wide scale
using RNA microarray technology. Microarrays are a so-
phisticated method for both hypothesis building and hy-
pothesis testing within the same experimental setup due
to the vast amount and large scale of obtained data with-
out limitation to a set of presupposed genes or regula-
tory pathways. However, to the best of our knowledge,only a few studies have been performed investigating
basic transcriptional responses to internal radionuclide
exposure to, e.g., 131I [21,22] or specifically 211At [19,20].
Furthermore, few robust molecular biomarkers for ioniz-
ing radiation exposure in vivo have been identified, since
most studies have been performed in vitro [16,17].
The purpose of this study was to investigate genome-
wide transcriptional responses over time in normal non-
thyroid tissues following intravenous 211At administration
in mice. The aim was to characterize tissue-specific
transcriptome responses and to identify potential in vivo
biomarkers for (very) low mean absorbed doses with sen-
sitivity to dose rate.
Methods
Radionuclide production and radioactivity measurements
211At was produced via the 209Bi(α,2n)211At reaction at the
Cyclotron and PET Unit at Rigshospitalet in Copenhagen,
Denmark. Preparation of free 211At was performed accord-
ing to Lindegren et al. [23]. The CRC-15R dose calibrator
ion chamber (Capintec, Inc., Ramsey, NJ, USA) was used
to measure 211At activity concentrations of stock solutions
prior to injection.
Estimation of absorbed dose
Calculation of organ-specific mean absorbed doses (Dorgan)
was performed according to the Medical Internal Radiation
Dose (MIRD) formalism, assuming homogeneous activity
distribution within each organ [24].
Dorgan ¼
~Aorgan 
X
i
niEiΦi
morgan
;
where ni is the yield for radiation i with energy Ei and
absorbed fraction Φi in the target organ with mass
morgan.
Organ-specific biodistribution data for 211At between
0 and 24 h was taken from literature [8]. The biodistri-
bution was assumed invariant from 24 h to 7 days. The
cumulated activity Ãorgan was estimated from 0 h to 7 days
using the trapezoidal rule. Dose contributions were only
considered from α-particles emitted by 211At and its
daughter polonium-211 (211Po). For all investigated tis-
sues, the absorbed fraction was set to 1 due to the short
mean range of emitted alpha particles [25].
Animal experiments
Adult female BALB/c nude mice (CAnN.Cg-Foxn1nu/Crl,
Charles River Laboratories International, Inc., Salzfeld,
Germany) were injected into the tail vein with 1.7 kBq 211At
in physiological saline solution (n = 3/group). The control
group was mock-treated with phosphate buffered sa-
line (n = 3). At 1 h, 6 h, and 7 days after injection, ani-
mals were anesthetized with sodium pentobarbital and
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after 24 h. The kidneys, liver, lungs, and spleen were ex-
cised, flash-frozen, and stored at −80°C until analysis. Cor-
tical and medullary kidney tissues were dissected and
prepared separately. In addition, two groups with two
mice each were treated as described above but injected
with 105 or 7.5 kBq 211At to deliver 1.4 Gy to the thyroid
over 1 and 6 h, respectively, and treated as described
above. Please see workflow diagram for overview on treat-
ment and sampling (Figure 1). All animal procedures were
approved by the Ethical Committee on Animal Experi-
ments in Gothenburg, Sweden.
Gene expression analysis
Total RNA was extracted from individual tissue samples
and concentration and integrity values were determined
as described previously [20]. All samples were validated
for subsequent analysis with a RIN value of at least 6.0.
RNA samples were analyzed on Illumina MouseRef-8
Whole-Genome Expression BeadChips (Illumina; San
Diego, CA, USA) using technical triplicates and proc-
essed at the Swegene Center for Integrative Biology
Genomics DNA Microarray Resource Center (SCIBLU;
Lund, Sweden). Image acquisition, raw signal quantifica-
tion, data preprocessing, and quantile normalization were
performed with Illumina and BioArray Software Environ-
ment (BASE) (SCIBLU) software as described previously
[20]. Subsequent data processing was performed with
Nexus Expression 2.0 (BioDiscovery; El Segundo, CA,
USA) as described elsewhere [26].
The false discovery rate for differentially expressed
transcripts was controlled according to the Benjamini-
Hochberg method [27] with an adjusted P value cutoff
of less than 0.01 and with a threshold of a 1.5-fold
change or higher. Enriched Gene Ontology (GO) terms
associated with a gene set were identified with a P value
cutoff of less than 0.05. The GO database (http://www.
geneontology.org) was used for analysis of associated GOFigure 1 Workflow diagram for overview on treatment and sampling
211At and killed after 1 h, 6 h, and 7 days or injected with 105 or 7.5 kBq 21
and spleen were excised, frozen and stored. Kidney cortex and kidney med
from tissue samples and subjected to microarray analysis. For details on daterms and biological processes [28]. Enriched biological
processes were categorized based on GO terms to estab-
lish comprehensive regulatory profiles according to cellu-
lar function as previously presented [20]. The intensity of
response was expressed as the percentage of scored vs. the
filtered number of transcripts calculated for all biological
processes grouped in a (sub)category. Please see workflow
diagram for overview on sample processing analytical end-
points (Figure 1). The gene expression data in this study
have been deposited in NCBI's Gene Expression Omnibus
(GEO accession GSE56894).
Results
Organ-specific absorbed doses
Administration of 1.7 kBq 211At solutions resulted in
very low to low mean absorbed doses in the liver, lungs,
spleen, and kidney tissues over 1 week (Table 1). One
hour after injection, mean absorbed dose was lowest in
the liver with 0.23 mGy and highest in the lungs with
1.9 mGy. One week after injection, the mean absorbed
dose ranged from 6.3 to 50 mGy for the investigated tis-
sues. The mean absorbed dose to the lungs was approxi-
mately threefold higher than to the spleen, sixfold higher
than to the kidneys, and eightfold higher than to the
liver. Compared with 1.7 kBq 211At, administration of
105 and 7.5 kBq 211At resulted in approximately 60-fold
higher mean absorbed doses over 1 h and approximately
fourfold higher mean absorbed doses over 6 h, respect-
ively. In thyroid tissue, absorbed dose was around 78-,
127-, and 184-fold higher after 1 h, 6 h, and 7 d, respect-
ively, compared with kidney tissue (data not shown).
Please note that analysis of transcriptional regulation
in thyroid in response to 211At is part of an ongoing
study.
Total transcriptional responses
The number of significantly upregulated transcripts from
1 h to 7 days in response to 1.7 kBq 211At varied between. Female BALB/c nude mice were intravenously injected with 1.7 kBq
1At and killed after 1 and 6 h, respectively. The kidneys, liver, lungs,
ulla were dissected and treated separately. Total RNA was extracted
ta processing and analysis, please refer to text.
Table 1 Tissue-specific absorbed doses
Mean absorbed dose (mGy)
211At activity (kBq) 1.7 105 1.7 7.5 1.7
Time point 1 h 1 h 6 h 6 h 7 days
Kidney cortex 0.29 18 2.6 11 7.6
Kidney medulla 0.29 18 2.6 11 7.6
Liver 0.23 14 2.0 8.9 6.3
Lungs 1.9 116 16 72 50
Spleen 0.86 53 5.7 25 14
Thyroid 23 1,400 320 1,400 1,800
Mean absorbed dose (mGy) to mouse tissues at the time of animal killing after
intravenous administration of 1.7, 7.5, or 105 kBq 211At. Calculations are based
on the Medical Internal Radiation Dose (MIRD) formalism [24] with biodistribution
data reported by Garg et al. [8].
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transcripts were downregulated. Upregulation dominated
over downregulation in two-thirds of all instances. The
lowest number of regulated transcripts was observed in
the kidney cortex after 6 h and in the other tissues after
7 days. In most tissues, an increased number of regulated
transcripts - although marginal for some instances - could
be seen with increased absorbed dose (rate) at 1 and 6 h
(Figure 2B). However, spleen tissue showed an inverse re-
sponse with a distinctly reduced number of significantly
regulated transcripts at the higher absorbed dose (rate) at
both time points (Figure 2B). Moreover, kidney medulla
and spleen showed an increased transcript regulation
at the higher dose rate (105 kBq administration, 1 h)
than at the lower dose rate (7.5 kBq administration, 6 h).
In contrast, the kidney cortex, liver, and lungs responded
more strongly to the lower dose rate.Figure 2 Number of significantly regulated transcripts. Comparison of
and downregulated (negative numbers) transcripts in the kidney cortex an
points after i.v. administration of 1.7 kBq 211At. (B) shows total transcript re
1.7 kBq compared to either 105 kBq 211At after 1 h or to 7.5 kBq 211At afterPotential dose rate-sensitive molecular biomarkers
The sample cohort was investigated for potential mo-
lecular biomarkers with sensitivity in the (very) low
absorbed dose range. In addition, the dose rate effect for
responses after 1 and 6 h was also analyzed. For the ma-
jority of transcripts regulated at all exposure conditions,
fold change values were lowest after 7 days (Figures 3
and 4). In kidney cortex, ten genes were significantly
regulated at all exposures, including two probe variants
for the Per1 gene (Figure 3A), all of which were continu-
ously upregulated. In the lungs and spleen, only two and
one gene(s) were significantly regulated at all exposures,
respectively (Figure 3B, C). Similar to kidney cortex,
neither the lungs nor spleen showed downregulation
among commonly regulated genes. Liver tissue showed
the highest yield with 32 significantly regulated genes
at all exposures, including two probe variants for the
Coq10b and Per1 genes (Figure 4). Among these 34
transcripts, 25 were upregulated and all transcripts showed
no change in direction of regulation with changing expos-
ure condition. In kidney medulla, no genes were signifi-
cantly regulated at all exposures within this sample cohort.
Among significantly regulated transcripts, the expres-
sion profile of potential molecular biomarkers is prefera-
bly a function of monotonous increase or decrease with
absorbed dose/dose rate. As such, fold change values
should be either higher or lower for increased activity at
both time points compared to 1.7 kBq with no change in
intensity of up- or downregulation relative to 1.7 kBq
between time points. In kidney cortex, the Sgk1, G6pc,
Dusp1, Angptl4, and Per2 genes showed this pattern for
potential biomarkers. In the lungs, the Per1 and Tsc22d3
genes also displayed this pattern. Although Tsc22d3 showedthe total number (no.) of significantly upregulated (positive numbers)
d medulla, liver, lungs, and spleen. (A) shows responses at various time
gulation at early time points dependent on dose rate, i.e., effects from
6 h.
Figure 3 Potential molecular biomarkers in the kidney cortex, lungs, and spleen for i.v. 211At administration. Differentially regulated
genes on the transcriptional level responding at all investigated time points in the kidney cortex (A), lungs (B), and spleen (C) after injection of
1.7, 7.5, or 105 kBq 211At. Note the difference in scaling of the y-axis compared with Figure 4.
Langen et al. EJNMMI Research  (2015) 5:1 Page 5 of 12the same pattern in spleen, the difference in fold change
values between activities at 1 h was comparatively low. In
the liver, 50% of the genes displayed this pattern, i.e., Fgb,
Mup4, Insig1, Osgin1, Egr1, Rnf125, Slc5a6, LOC100047579,
Dbp, Cyp4a14, Angptl4, two probe variants for Per1, Lgals4,
Kcnk5, two probe variants for Coq10b, and Tsc22d3. It
should be noted that differences in fold change within this
pattern, i.e., between 1.7 kBq administrations compared to
105 kBq after 1 h or 7.5 kBq after 6 h, respectively, varied
strongly between time points, genes, and tissues. In
this regard, Per1 (Illumina probe ID ILMN_2813484)
in kidney cortex and Tef in liver showed this regulatory
pattern, but differences in fold change values between
both activities were below 3% at 1 and 6 h, respectively.Figure 4 Potential molecular biomarkers in the liver for i.v. 211At adm
responding at all investigated time points in the liver after injection of 1.7
compared with Figure 3.Response profiles of biological processes
Transcriptional response to 1.7 kBq 211At was investi-
gated on the level of cellular function based on estab-
lished categorization of enriched biological processes
(Figure 5). Complete lists of categorized biological pro-
cesses are provided for all tissues in Additional file 1:
Table S1, Additional file 2: Table S2, Additional file 3:
Table S3, Additional file 4: Table S4, and Additional
file 5: Table S5. Response patterns within subcategories
of biological processes indicated tissue specificity. A
common trend in regulatory intensity was seen in the
tissues, with the vast majority of regulation incidences
ranging from very low (below 3%) to low (from 3% to
9%). No response was observed for DNA damage andinistration. Differentially regulated genes on the transcriptional level
, 7.5, or 105 kBq 211At. Note the difference in scaling of the y-axis
Figure 5 (See legend on next page.)
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Figure 5 Response profiles of enriched biological processes categorized after cellular function. Significantly regulated transcripts were
enriched for biological processes which were grouped in respective categories and subcategories of higher level cellular function. The percentage of
scored vs. filtered transcripts is illustrated as very low <3%, low 3% to 9%, medium 10% to 29%, high 30% to 49%, and very high ≥50% and presented
as very light blue, light blue, blue, dark blue, and very dark blue, respectively. Further information on categorized biological processes and absolute
transcript numbers are presented in Additional file 1: Table S1, Additional file 2: Table S2, Additional file 3: Table S3, Additional file 4: Table S4, and
Additional file 5: Table S5 for the kidney cortex and medulla, liver, lungs, and spleen, respectively. Absorbed dose received from 1.7 kBq 211At i.v. administration
during respective time frame.
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matin organization occurred only at 1 h in kidney me-
dulla. Gene expression integrity showed no regulation
in either kidney medulla or spleen at any time point.
Response to maintaining cellular integrity was more
pronounced than for maintaining DNA or gene expres-
sion integrity in all tissues, although regulatory pat-
terns differed between all tissues. Several subcategories
in cell cycle and differentiation were not regulated in
an individual tissue, yet no specific subcategory was
void of responses in all tissues. In cell communication,
signal transduction was affected in every tissue for all
or most exposure conditions, while intercellular signal-
ing was only affected after 1 h in spleen. Metabolism
was diversely regulated in all tissues. The strongest
overall response was seen in liver, followed by kidney
cortex and medulla. Stress responses were observed in
all tissues with general dominance of immune responses
and unspecific responses (Other). In the category of or-
ganismic regulation, regulation incidences for behavior
were not observed in both kidney tissues and lungs and
neither for ontogenesis in the lungs nor for reproduction
in the kidney cortex, liver, lungs, and spleen.
Discussion
The synthetic radiohalogen 211At and the 211Po daughter
emit two main α-particles, i.e., 5.87 and 7.45 MeV, which
have an approximated range of 48 and 70 μm in liquid
water, respectively [25]. Alpha particles are densely ion-
izing and cause non-homogeneous energy deposition
within cells or tissues. The degree of homogeneity in cel-
lular irradiation - i.e., the fraction of non-hit, single-hit,
or multi-hit cells in a population - most likely influences
the biological response of a given tissue. This response
depends not only on the amount of administered activity
and tissue-specific uptake and clearing rates but also on,
e.g., organ morphology, tissue structure, and size and
density of cells ([29], Josefsson A, Forssell-Aronsson
E. Microdosimetric analysis of the radio halogens 123I, 124I,
125I, 131I and 211At, Submitted). Non-homogeneous irradi-
ation may result in non-linear response to absorbed dose
on the tissue level and/or increased intensity of, e.g.,
non-targeted effects [30]. Microdosimetric consider-
ations of 211At exposure in vivo and the relevance ofnon-homogeneous irradiation at very low to low absorbed
doses have been discussed previously in a related study
[20]. Accordingly, very low to low absorbed doses in kid-
ney, liver, lungs, and spleen tissues corresponded to non-
homogeneous irradiations with large fractions of non-hit
cells. With increased absorbed dose, the fraction of single-
hit and multi-hit cells increases. In this context, it should
be pointed out that genome-wide transcriptional re-
sponses were obtained from homogenized tissue samples.
The presented data gives information on significant bio-
logical responses within tissue-specific cell populations in
an in vivo context. Nevertheless, the non-homogeneous
nature of α-particle exposure at (very) low absorbed doses
from 211At introduces the question how much of the sig-
nificant transcript response originated from the (single or
multi) hit fraction(s) and to what extent the non-hit frac-
tion contributed to the observed effects in each tissue.
The total number of significantly regulated transcripts
in response to 1.7 kBq 211At varied with time and tissue
type. Previous studies demonstrated that differential tran-
script expression in thyroid and non-thyroid tissues varied
with 211At activity at 24 h after administration [19,20].
Taken together, these findings substantiate for the in vivo
setting that ionizing radiation-induced responses strongly
depend on exposure condition and time course. Recently,
Heinonen and colleagues estimated differential expression
time periods after stress exposure using a novel Bayesian
likelihood ratio test [31]. Among others, the group mea-
sured transcript profiles of 77 differentially expressed
genes in primary human endothelial cells in vitro after ex-
ternal irradiation of 2 Gy with a 137Cs source, demonstrat-
ing that the maximum differential expression (>1.5-fold
change) occurred between 8 and 12 days after irradiation.
Time-dependent change in differential expression consti-
tutes an important factor in transcriptional analysis and,
specifically, biomarker discovery. In the present study
using internal radionuclide exposure, differences in differ-
ential expression between time points were influenced not
only by, e.g., the biological response time of certain regula-
tory events but also by continuous irradiation and in-
creased absorbed dose over respective periods. Hence, it is
unfeasible to analyze time between exposure and effect as
an individual factor in this setting. An external irradiation
setup would be required to allow for both singular and
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tween biological response time and (extent of) induced
regulation.
In the dose-rate study, injected activities of 105 and
7.5 kBq were chosen so that the thyroid gland would
receive a mean absorbed dose of 1.4 Gy over 1 and 6 h,
respectively. Since the thyroid is a regulatory organ
that is presumed to have a potential impact on non-
thyroid tissue responses [20], we chose this setup to
keep absorbed dose in thyroid tissue constant over
both time periods. This would constrict the variable of
absorbed dose dependence in the systemic setting of a
regulatory organ impacting target organs. Concerning
non-thyroid tissues, tissue-specific variations in 211At
uptake and clearing rates did not give exact matching
of mean absorbed dose within this setup, but respect-
ive mean absorbed doses lay at similar low levels.
Nevertheless, transcript regulation showed sensitivity
to differential dose rate exposure in this setup for all
tissues. These regulatory responses also showed pro-
nounced differences compared with thyroid tissue, which
is subject of an ongoing study.
An inverse dose rate effect on total transcript regula-
tion was observed in the kidney cortex, liver, and lungs.
The inverse dose rate phenomenon has been demon-
strated for different exposure conditions and biological
end points, for instance for mutation induction in hu-
man lymphoblasts in response to 137Cs γ-rays [32], dele-
tions size in the HPRT locus in human lymphoblastoid
cells following 200 keV X-ray exposure [33], micronuclei
induction in Lewis lung carcinoma cells exposed to 60Co
γ-rays [34], and cytokine gene expression in human glio-
blastoma cell lines irradiated with 137Cs γ-rays [35]. A
cell cycle-dependent phase of sensitivity has been pro-
posed to explain the inverse dose rate effect, meaning
that increased irradiation time at decreased dose rate in-
creases the probability of a cell to enter a sensitive phase
during cell-cycle progression [36,37]. A saturable inter-
mediate state has been hypothesized as well, which postu-
lates that an increase in probability for damage induction
would not increase proportionally with increased number
of hits to a cell [37,38]. Brenner and colleagues concluded
in their modeling approach using the linear-quadratic +
resensitization formalism that ‘all potential explanations of
inverse dose rate effects predict that, at appropriately low
doses, no dose rate effects of any kind are expected’ [38].
This statement provokes the question on the nature of the
inverse dose rate effects observed for differential tran-
script expression at the (very) low absorbed doses from
α-radiation observed in this study. Assuming relatively
homogeneous tissue morphology and radionuclide dis-
tribution, one out of one thousand cells is estimated to
be hit in the mGy range with very low probability for
more than one hit per cell. Since the largest amount ofcells contributing to expression data are within the
non-hit fraction under these exposure conditions, com-
plex non-targeted effects may contribute to non-linearity
of responses. Furthermore, the relatively high LET value
and biological effectiveness of 211At-emitted α-particles
may increase the inverse dose rate effectiveness factor
compared with γ-rays and X-rays. It is unclear at this
point whether the transcripts that exhibited an inverse
dose rate effect are regulated as an immediate response to
particle hits or if their regulation is determined by regula-
tory networks in dependence of additional factors. The
finding that dose rate effects differed between tissues im-
plies an additional degree of complexity for radiation re-
sponses to (very) low absorbed doses or dose rates in vivo.
Biological response on the organismic level needs to be
understood in a dynamic context where some tissues
would respond more intensively at a given time point
or to a certain dose rate, while other tissues would
show a less pronounced response; yet this relation
might change or invert over time and with regard to
dose rate.
A biomarker for ionizing radiation exposure should be
indicative of a certain radiation-induced effect, such as
molecular damage to the DNA or impaired cellular func-
tion. An ideal biomarker should be easily quantifiable
and constitute a molecule (or a group of molecules) that
changes in concentration or is modified upon exposure.
The response should change monotonously with absorbed
dose and occur early upon irradiation and remain detect-
able after a long time period. Sensitivity over a wide
absorbed dose range is desirable but not mandatory, since
a panel of biomarkers could be assorted covering a wider
range. A biomarker should be sensitive to low dose rate
and, ideally, indicate low, medium, or high dose rate ex-
posure with, e.g., changes in time-of-onset and intensity of
response. Transcriptional regulation responds to a stressor
in a sensitive manner and continuous dysregulation of
transcript expression can be expected to manifest itself
earlier than detrimental changes on the protein level.
This is an advantage of transcriptional biomarkers
compared to protein biomarkers or general markers of
tissue function. In a low dose exposure setting, an
acute radiation response and related tissue damage are
not expected, as opposed to an increased risk for cancero-
genesis or latent damage. Correlation between early effects
upon exposure and long-term health effects requires sub-
stantial knowledge of overall transcriptomic responses and
individual gene regulation patterns. This approach can be
used to establish risk estimation based on absorbed dose
or, in critical cases, justify tissue biopsies of risk organs.
In this study, we investigated the up- or downregulation
of transcript expression for the discovery of individual mo-
lecular biomarkers. BALB/c nude mice were chosen for
these experiments since in vivo models for radionuclide
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tumor xenografts. The presented results should be applic-
able in that analytical context when studying normal tissue
effects of radiolabeled agents in tumor-bearing mice. In
this context, it should be noted that reduced expres-
sion of the DNA-dependent protein kinase catalytic
subunit (DNA-PKcs) and single nucleotide polymor-
phisms (SNPs) in Prkdc have been reported for several
BALB/c strains which affected DNA repair proficiency
upon ionizing radiation exposure [39-43]. To the best
of our knowledge, the specific strain used in this study
has not been categorized regarding DNA repair defi-
ciency, but it is assumed that the genetic background ex-
hibits similarly increased radiation sensitivity. Accordingly,
the observed responses can be related to radiation sensitive
individuals in a clinical setting.
For the kidney cortex, liver, lungs, and spleen, several
genes were identified that followed a potentially indica-
tive pattern across all exposures, i.e., a consistent regula-
tory change between lower and higher injected activity
at 1 and 6 h with either a direct or inverse dose rate
effect - while showing a consistent trend relative to
1.7 kBq over time. Several of these genes were shared
between tissues: angiopoietin-like protein 4 (Angptl4)
was regulated in both the kidney cortex and liver and
was nearly regulated in all tissues and at all mean
absorbed doses (0.064 to 42 kBq 211At) after 24 h in
the previous study [20]. The Angptl4 gene product is
thought to modulate vascular activity and tumor cell
motility and invasiveness, which implies its signifi-
cance for tumor progression and metastasis [44-46].
The prognostic value of Angptl4 deregulation in ion-
izing radiation-induced cancerogenesis is promising,
but accumulating evidence suggests that the function
of Angptl4 highly depends on, e.g., proteolytic pro-
cessing and posttranslational modifications and thus
can have opposite effects on vascular permeability in
different cancers [47,48]. The versatile functions of
Angptl4 impede further speculation on long-term ef-
fects after 211At exposure, or ionizing radiation in
general, at this point. Long-term studies are needed
in order to evaluate whether or not the observed re-
sponse is indicative of radiation-induced tumorigen-
esis or carcinogenesis at these early time points or if
transcriptional regulation of Angptl4 responds in a
different context.
Either Per1 or Per2 (periodic clock genes 1 and 2)
were commonly regulated in the kidney cortex, liver,
and lungs at all exposure conditions. In our previous
study on non-thyroid tissues, Per1 also showed significant
upregulation in these tissues after 24 h in an absorbed
dose range from several mGy to around 1 Gy, i.e., specific-
ally after administration of 0.64, 14, and 42 kBq 211At
(data not shown in Langen et al. [20]; please refer to GEO:GSE40806). In thyroid, Per1 was also consistently upregu-
lated after 24 h at these injected activities, i.e., 0.5, 11, and
32 Gy, respectively (see supplemental material of Rudqvist
et al. [19]). Per2, on the other hand, was significantly regu-
lated only in liver and thyroid after 24 h in the low
injected activity range. In both tissues, Per2 was consist-
ently downregulated with a similarly low differential ex-
pression ranging between −1.7 and −2.2-fold change.
Taken together, we demonstrated that Per1 and Per2
responded differently in different tissues and across a
wide-absorbed dose regimen from mGy to over 32 Gy. Per
genes encode for negative regulators in the circadian feed-
back loop, thus regulating metabolism as well as various
other cellular processes and circadian-dependent gene ex-
pression [49]. Disturbance of the circadian clock has been
linked to cancer; specifically, deregulation of Per1 and
Per2 have been connected to gastric cancer and suggested
as prognostic markers [49-51]. Moreover, long-term ef-
fects in tumor suppression by Per proteins have been
demonstrated in context with ionizing radiation exposure
[52]. At a sub-lethal dose of 4 Gy γ-radiation, mPer2 mu-
tant mice showed graying of the coat after approximately
2 months and/or developed lymphoma after 5 months at
a significantly increased rate compared with wild-type
mice [52]. Consequently, disruption of Per gene expres-
sion can be expected to dampen - if not abolish - impede
this protective feature and result in increased cancer risk.
Whether responses in Per1 and Per2 are indicative of
radiation-induced malignancies or if their regulation is
mainly affected by metabolism and circadian rhythm
needs to be addressed in further studies allowing for strict
separation of these factors.
Tsc22d3 (TSC22 domain family, member 3) was up-
regulated in the liver, lungs, and spleen at all treatment
conditions. This finding was in agreement with a study
by Koike and colleagues demonstrating upregulation of
TSC22 in normal human epidermal keratinocytes after 4
and 8 h following exposure to 10 Gy X-ray radiation
[53]. In our previous study, Tsc22d3 did not exhibit sig-
nificant regulation after 24 h in liver or kidney tissues,
and only few regulation incidences in lungs and spleen
(data not shown in Langen et al. [20]; please refer to
GEO:GSE40806). Tsc22d3 was also not significantly reg-
ulated after 24 h in thyroid across an absorbed dose
range from 0.05 to 32 Gy (see supplemental material of
Rudqvist et al. [19]). In comparison with the aforemen-
tioned Per transcripts, Tsc22d3 appeared to respond in a
more restrictive fashion. The expressed protein shares
sequence similarities with leucine zipper proteins, implying a
function as a transcription factor [54]. Regulation of Tsc22d3
appears to have a key function in anti-inflammatory and im-
munosuppressive effects of glucocorticoids and interleukin-
10 [55]. Furthermore, interactions between Tsc22D3 and
transcription factors nuclear factor NF-kappa-B p105
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subunit (NFKB2) have been demonstrated [55]. The
knowledge base, however, is still scarce regarding long-
term effects of Tsc22d3 deregulation, and prognosis of
late effects from 211At-induced upregulation cannot be
made at this point. In a broader sense, even robust
molecular biomarkers would underlie regulation net-
works, which would render extrapolation of effects
over time difficult. Hence, observed responses in indi-
vidual genes should be considered in the broader con-
text of regulatory networks within a cell and in the
larger context of tissues and organs within the body.
Cellular function (the quality of transcriptional effects) was
characterized according to enriched transcript-associated
biological processes. The response patterns differed between
tissues at similar absorbed dose level - specifically comparing
kidney cortex, kidney medulla, and liver - which was in
agreement with a study demonstrating that ionizing
radiation-induced effects are not preprogrammed gen-
etic responses but rather depend on tissue origin [56].
The major lesion type of ionizing radiation is consid-
ered to be the induction of DSB in the DNA molecule.
The LET value of 211At-emitted α-particles is nearly
100 keV/μm with a high effectiveness of producing
DSB [2,3], which should be considered in the analysis
and interpretation of induced effects. In the present
study, DNA damage and repair pathways did not show
transcriptional response in enriched biological pro-
cesses. A fold change value of at least 1.5 was chosen
to exclude a large proportion of weakly responding
genes and identify more pronounced changes in regu-
lation, and accordingly, more suitable candidate genes
(transcripts). In another research context, a somewhat
lower fold change threshold might be used which would
show more weakly responding genes (transcripts). An-
other factor that may lead to false-negative observation is
data convolution from mixed cell populations, i.e., signifi-
cant responses in a certain cell type may be dampened
due to low cell type frequency. Nevertheless, when the
DNA damage burden does not exceed the level of DNA
damage recognition, transcriptional regulation of respect-
ive proteins is not expected. Accordingly, responses in
DNA damage and repair processes may not be sensitive
biomarkers in the low-dose regimen. However, chromatin
organization was strongly affected after 1 h in kidney me-
dulla and also showed response to at least one absorbed
dose level after 24 h in all of the investigated tissues in the
previous study [20]. Based on studies by Bakkenist and
Kastan, chromatin organization was speculated to be a po-
tential biomarker for ionizing radiation exposure [57]. The
work indicated that activation of the ataxia-telangiectasia
mutated (ATM) protein - a crucial player in DNA damage
recognition - potentially results from structural changes of
chromatin organization and may not strictly depend ondirect protein-DNA binding [57]. In fact, responses in
chromatin organization were detected in each of the in-
vestigated tissues after 24 h at certain (very) low absorbed
doses from 211At as previously reported [20]. These find-
ings suggest monitoring of biological processes for chro-
matin organization, i.e., respective key genes involved in
process regulation, as potential in vivo biomarkers for
(very) low absorbed doses of ionizing radiation. In this re-
gard, chromatin organization may exhibit increased bio-
marker sensitivity for α-emitters compared to β-emitters
due to the higher probability for producing DSB lesions
per decay event.Conclusions
In conclusion, the quality and quantity of transcriptional
responses to i.v. administration of 1.7, 7.5, or 105 kBq 211At
in BALB/c nude mice were tissue-specific. Total transcript
regulation after 1 h, 6 h, or 7 days showed dose rate de-
pendency even in the (very) low absorbed dose range. Fur-
thermore, the extent as well as relative increase or decrease
in number of significantly regulated transcripts varied be-
tween time points and tissues. Categorization of enriched
biological processes revealed diverse and tissue-specific
regulation of cellular function after 211At administrations.
Angptl4, Per1 and Per2, and Tsc22d3 showed the highest
potential for being biomarkers of low-dose α-particle
exposure. Identifying detrimental dysregulation of gene
expression early after treatment is an essential part for
counteracting toxic side effects in clinical practice. A
deterioration of tissue function was not expected at the
investigated time points after (very) low-dose exposure. In
long-term studies, health effects such as decreased func-
tion or increased rate of cancerogenesis in respective tis-
sues could be measured in parallel to genome-wide
transcriptional analysis and correlated to the early tran-
scriptional effects reported here.
Significant regulation of these transcripts, however, was
not detected in every tissue, which may further indicate
that tissue specificity is a relevant factor not only for ioniz-
ing radiation-induced cellular responses but also for ro-
bust biomarkers. Exposure of normal tissues to low-dose
ionizing radiation is a critical parameter in radiation ther-
apy. The relationship between early cellular responses and
late organic outcomes is a relevant aspect for risk limita-
tion and optimization of treatment planning. Further re-
search on genome-wide transcript regulation in vivo is
indispensable to build the knowledge base on normal tis-
sue responses to ionizing radiation exposure.Additional files
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